Journal article

Assessment of the DTI-ALPS Parameter Along the Perivascular Space in Older Adults at Risk of Dementia

Christopher E Steward, Vijay K Venkatraman, Elaine Lui, Charles B Malpas, Kathryn A Ellis, Elizabeth V Cyarto, Lucy Vivash, Terence J O'Brien, Dennis Velakoulis, David Ames, Colin L Masters, Nicola T Lautenschlager, Roland Bammer, Patricia M Desmond

JOURNAL OF NEUROIMAGING | WILEY | Published : 2021

Abstract

BACKGROUND AND PURPOSE: Recently, there has been growing interest in the glymphatic system (the functional waste clearance pathway for the central nervous system and its role in flushing solutes (such as amyloid ß and tau), metabolic, and other cellular waste products in the brain. Herein, we investigate a recent potential biomarker for glymphatic activity (the diffusion tensor imaging along the perivascular space [DTI-ALPS] parameter) using diffusion MRI imaging in an elderly cohort comprising 10 cognitively normal, 10 mild cognitive impairment (MCI), and 16 Alzheimer's disease (AD). METHODS: All 36 participants imaged on a Siemens 3.0T Tim Trio. Single-SE diffusion weighted Echo-planar ima..

View full abstract

Grants

Awarded by Australia's National Health and Medical Research Council


Funding Acknowledgements

The authors declare that this study received funding from Australia's National Health and Medical Research Council; Contract grant number: 1005492. Funding for the AIBL study is provided by the CSIRO Flagship Collaboration Fund and the Science and Industry Endowment Fund (SIEF) in partnership with Edith Cowan University (ECU), Mental Health Research Institute (MHRI), Alzheimer's Australia (AA), National Ageing Research Institute (NARI), Austin Health, CogState Ltd., Hollywood Private Hospital, and Sir Charles Gardner Hospital. The study also received funding from the National Health and Medical Research Council, the Dementia Collaborative Research Centres program (DCRC2), and The McCusker Alzheimer's Research Foundation and Operational Infrastructure Support from the Government of Victoria. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. The imaging data and cognitive data collection for the Alzheimer's cohort was funded by Velacor Therapeutics as part of the VELACOR-002 trial.